JIMRO

What JIMRO does

JIMRO Co., Ltd. (株式会社JIMRO) is a Japanese medical device manufacturer founded in 1977 and headquartered in Takasaki, with additional offices in Tokyo and Osaka and between 101 and 250 employees. The company specializes in apheresis technology, particularly Granulocyte and Monocyte Adsorptive Apheresis (GMA), delivered through its flagship Adacolumn® device, which selectively removes activated granulocytes and monocytes from patient blood. Originally developed for inflammatory bowel disease (IBD), Adacolumn® received Japanese manufacturing and marketing approval for a sepsis indication in November 2024, with national insurance coverage effective August 2025, and supporting clinical data published in the Artificial Organs journal in February 2025.

The company's product portfolio extends beyond apheresis to include the AJIRO® colonic stent for gastrointestinal applications and the Tron FX® thrombus removal device launched in February 2019. JIMRO operates a sales-led go-to-market targeting healthcare professionals and medical institutions in Japan through direct sales representatives and medical-professional-focused channels, including dedicated medical portals, clinical seminars, and participation in IBD-related medical societies and World IBD Day awareness activities. The company maintains affiliations with multiple Otsuka group entities via group-company listings, suggesting a potential corporate relationship within the larger Otsuka holding structure.

JIMRO generates revenue primarily through hardware sales of its medical devices to Japanese hospitals and clinics. Pricing is not publicly disclosed, and the company has no visible international operations, operating exclusively within Japan's domestic market. The company's strategic momentum is concentrated on expanding Adacolumn®'s clinical indications from IBD into sepsis and adjacent inflammatory conditions, supported by ongoing clinical research, regulatory milestones, and incremental portfolio diversification through the 2017 acquisition of Biomedical Solutions and the Tron FX® device launch.

Name

JIMRO

Legal name

株式会社JIMRO

Website

https://jimro.co.jp

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

101–250 employees

Short description

JIMRO is a Japanese medical device manufacturer founded in 1977 that specializes in apheresis technology, primarily the Adacolumn® GMA device for inflammatory bowel disease and sepsis, alongside gastrointestinal and thrombectomy devices, selling directly to hospitals and medical institutions in Japan.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Apheresis medical devices
• Gastrointestinal stents
• Thrombectomy devices
• Inflammatory bowel therapy
• Blood purification systems

Headquarters

HQ city

Takasaki

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: JIMRO generates revenue through the sale of medical devices including apheresis columns, stents, and thrombectomy devices to healthcare institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

JIMRO manufactures and sells medical devices, primarily apheresis columns (Adacolumn) for Granulocyte and Monocyte Adsorptive Apheresis (GMA) therapy used in inflammatory bowel disease (IBD) and sepsis treatment. The company also produces the AJIRO colon stent for gastrointestinal applications and the Tron FX thrombectomy device for vascular clot removal. These devices are sold and rented to hospitals and medical institutions in Japan.

Product overview

JIMRO is a Japanese medical device company specializing in apheresis devices and gastrointestinal medical devices. The core product portfolio centers on Adacolumn, an apheresis device for GMA (Granulocyte and Monocyte Apheresis) therapy, which has expanded from its original IBD indication to sepsis treatment. The company also offers the AJIRO Colon Stent for gastrointestinal applications and the Tron FX Thrombus Removal Device for vascular procedures. These products serve the medical professional segment with devices for inflammatory disease treatment and digestive tract interventions.

Differentiator

Problem solved

Functional benefit

Brands

• Adacolumn (アダカラム): Apheresis device product for IBD and sepsis treatment
• AJIRO Colon Stent (AJIRO大腸用ステント)
• Tron FX

Products and services

• Adacolumn (アダカラム) An apheresis device that performs Granulocyte and Monocyte Apheresis (GMA) to selectively remove activated granulocytes and monocytes from the blood. Originally developed for inflammatory bowel disease (IBD) treatment and expanded to sepsis treatment following regulatory approval in Japan. Sold to hospitals and medical professionals for patient therapy.
• AJIRO Colon Stent (AJIRO大腸用ステント) A gastrointestinal stent device designed for colon applications, used by gastroenterologists and interventional endoscopists for digestive tract procedures.
• Tron FX Thrombus Removal Device (Tron FX血栓除去デバイス) A thrombectomy device used for the removal of thrombus (blood clots) in vascular procedures, marketed to hospitals and vascular specialists.

Quantifiable outcome

• Adacolumn approved for sepsis treatment in Japan (November 2024)
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor.

• Otsuka Pharmaceutical Co., Ltd. (大塚製薬)minorOthersJIMRO is listed among Otsuka group companies on their website footer links. Otsuka Pharmaceutical appears as a related group company, suggesting an affiliation or corporate relationship within the larger Otsuka holding structure.
• Otsuka Medical Devices Co., Ltd. (大塚MDB)minorOthersListed as a related Otsuka group company. Otsuka Medical Devices operates within the medical device segment of the Otsuka group.
• Otsuka Corporation (大塚製薬)minorOthersListed as a related Otsuka group company in footer navigation.
• Otsuka Chemical Co., Ltd. (大塚化学)minorOthersListed as a related Otsuka group company in footer navigation.
• Otsuka Frontier Co., Ltd. (大塚フロンティア)minorOthersListed as a related Otsuka group company in footer navigation.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JIMRO